Seeding drug discovery: integrating telomerase cancer biology and cellular senescence to uncover new therapeutic opportunities in targeting cancer stem cells

被引：18

作者：

Keith, W. Nicol

Thomson, Catherine M.

Howcroft, Jill

Maitland, Norman J.

Shay, Jerry W.

机构：

[1] Univ Glasgow, Ctr Oncol & Appl Pharmacol, Canc Res UK Beatson Labs, Glasgow G61 1BD, Lanark, Scotland

[2] Pleiad Devices, Perth, ON, Canada

[3] Univ York, YCR Canc Res Unit, York YO10 5DD, N Yorkshire, England

[4] Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA

来源：

DRUG DISCOVERY TODAY | 2007年 / 12卷 / 15-16期

关键词：

D O I：

10.1016/j.drudis.2007.06.009

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Telomerase activation is a hallmark of cancer. Advancement of telomerase as a therapeutic drug target has paved the way for translational opportunities in the related fields of senescence and cancer stem cells. Here, lessons may be learnt that can be applied to drug discovery, particularly with regard to the need to appreciate the relationships between telomerase, senescence and cancer stem cells. When considered as a time line to clinical trial, targeting of telomerase is leading the way to clinical proof-of-concept, with senescence and the cancer stem cell phenotype driving research concepts vital to maintaining a clinical development pipeline.

引用

页码：611 / 621

页数：11

共 54 条

[1]

ALHAJI M, 2007, CURR OPIN ONCOL, V19, P16

[2] Validating cancer drug targets [J].